Home
About Us
Membership
Member Biography

Member Biography

Tarah Ballinger, MD

Tarah Ballinger, M.D.

Phone: (317) 944-0920, Patient issues/appointments

Appointments

Associate Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Vera Bradley Foundation Scholar in Breast Cancer Research
Full member, Cancer Prevention and Control

My overarching research goal is to better understand the relationship between body composition, specifically bone and lean and fat tissue, with cancer incidence, outcomes, and side effects of cancer directed therapies, with a focus on breast cancer survivors. In particular, while a large organ system, muscle tissue is relatively underexplored in the pathogenesis of breast cancer and is affected by a large portion of our current therapies.

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy(POSITIVE)A221405/IBCSG48-POSITIVE

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.S1418/BR006

A quality improvement project to increase knowledge and referrals to the IU breast cancer prevention programCTO-IUSCC-0718

Phase 1a/1b Trial of Exercise Treatment with Concurrent First-Line Therapy for Hormone Receptor Positive Metastatic Breast CancerCTO-TBCRC054

Exercise in Metastatic Breast cancer: EMBodyCTO-IUSCCC-0781

CLUSTER RANDOMIZED CONTROLLED TRIAL OF PATIENT AND PROVIDER DECISION SUPPORT TO INCREASE CHEMOPREVENTION INFORMED CHOICE AMONG WOMEN WITH ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU - MAKING INFORMED CHOICES ON INCORPORATING CHEMOPREVENTION INTO CARE (MiCHOICE)CTO-SWOG-S1904

Understanding and Predicting Breast Cancer Events After TreatmentWF-97415

Assessing Exercise Behavior and Preferences Among Patients and Oncologists at Indiana University Simon Cancer CenterIUSCC-0690

A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive, HER2-positive breast cancer (ADEPT) CTO-20-347

Identifying gaps in breast cancer interception for high-risk women within IU HealthCTO-IUSCCC-0818

Examining Genetic Ancestry, Allostatic Load and Treatment Completion among Patients with Breast CancerCTO-2022C0174

COGNITIVE TRAINING FOR CANCER RELATED COGNITIVE IMPAIRMENT IN BREAST CANCER SURVIVORS: A MULTI-CENTER RANDOMIZED DOUBLE- BLINDED CONTROLLED TRIALCTO-NRG-CC011

NearWave optical molecular monitoring for predicting complete pathological response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer patients CTO-IUSCCC-0880

Understanding the Perception and Perceived Barriers of Participating in an Exercise Intervention in Women Living with Metastatic Breast CancerCTO-IUSCCC-0879

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)CTO-NRG-BR009

EXAMINING THE ROLE OF ALLOSTATIC LOAD IN RACIAL DISPARITIES IN INTRINSIC BREAST CANCER SUBTYPE AND AS A PROGNOSTIC MARKERCTO-2023C0120

Targeted Prevention Of Postpartum-Related Breast CancerCTO-MC220301

Exercise Habit for Breast Cancer Risk Reduction- A Randomized Clinical Trial: EXTENSION Study CTO-IUSCCC-0861

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)CTO-S2010

Culturally adapting an exercise intervention for Black women receiving chemotherapy for breast cancerHEMO-IIR-CAEIBW

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)CTO-J6M-MC-JSGD

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physician s Choice in Advanced Metastatic Breast Cancer (Bria-ABC)CTO-BC-IMT-04

Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer CTO-ALTE2131

A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS<=25 (RxFINE-Low)CTO-EA1242

A Phase II Single-Arm Pilot Study of Hydroxychloroquine for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS)CTO-IUSCCC-0959

Remote Exercise to Attenuate Chemotherapy Toxicity in Black Women With Breast Cancer (REACT)IUSCCC-0967

A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant DiseaseCTO-J2R-MC-YAAD

Headlines & highlights

Simon Says Expert Series featuring Tarah Ballinger

Working out cancer: The power of movement before, during and after cancer

September 2026

Esophageal Cancer Awareness: Gastroesophageal Reflux, Cancer & More

April 2023

Get a Move on Cancer: Impact of Physical Activity in Prevention, Treatment and Survivorship

September 2021

#ResearchCuresCancer

Support Our Research